pubmed.ncbi.nlm.nih.gov

Anorectal dysfunction in multiple sclerosis: a systematic review - PubMed

Anorectal dysfunction in multiple sclerosis: a systematic review

Sanober Nusrat et al. ISRN Neurol. 2012.

Abstract

Constipation and fecal incontinence are common in patients with neuromuscular diseases. Despite their high prevalence and potential impact on overall quality of life, few studies have addressed anorectal dysfunction in patients with multiple sclerosis (MS). The goal of this paper is to define the prevalence, pathophysiology, impact, and potential treatment of constipation and incontinence in MS patients. Methods. The PubMed database was searched for English language publications between January 1973 and December 2011. Articles were reviewed to assess the definition of the study population, duration, type and severity of MS, sex distribution, prevalence, impact, results of physiologic testing, and treatments. Results. The reported prevalence of constipation and fecal incontinence ranged around 40%. Anorectal dysfunction significantly affected patients with nearly 1 in 6 patients limiting social activities or even quitting work due to symptoms. Caregivers listed toileting as a common and significant burden. The only randomized controlled trial showed a marginal improvement of constipation with abdominal massage. All other reports lacked control interventions and only demonstrated improvement in individuals with milder symptoms. Conclusion. Anorectal dysfunction is a common manifestation in MS that significantly affects quality of life. Therapies are at best moderately effective and often cumbersome, highlighting the need for simple and more helpful interventions.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Strategy and results of the PubMed search.

Figure 2
Figure 2

The scatter plots show the study populations and prevalence of (a) constipation, (b) fecal incontinence, and (c) coexisting constipation and fecal incontinence in MS patients.

Similar articles

Cited by

References

    1. Alkhawajah M, Oger J. When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? Multiple Sclerosis International . 2011;2011:11 pages.724871 - PMC - PubMed
    1. Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews Neurology . 2012;8(1):13–21. - PubMed
    1. Kister I, Chamot E, Bacon JH, Cutter G, Herbert J. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Multiple Sclerosis . 2011;17(6):725–733. - PubMed
    1. Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Current Medical Research and Opinion . 2009;25(4):869–877. - PubMed
    1. Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975–2009) Multiple Sclerosis . 2012;18(4):442–450. - PubMed

LinkOut - more resources